Abstract: Eosinophilic solid and cystic (ESC) renal cell carcinoma (RCC) has recently been described as a potentially new subtype of RCC based upon morphologic and immunohistochemical features. These neoplasms typically demonstrate solid and cystic architecture, and the neoplastic cells contain voluminous eosinophilic cytoplasm with granular cytoplasmic stippling. There is frequently focal immunoreactivity for cytokeratin 20. Although the initial cases all occurred in adult females and had benign outcome, we recently expanded the proposed spectrum of this neoplasm to include pediatric cases, multifocal neoplasms, and a case with hematogenous metastasis. ESC has been postulated to be analogous to a subtype of RCC consistently identified in tuberous sclerosis complex patients, and while previous work has demonstrated loss of heterozygosity at the TSC1 locus and copy number gains at TSC2 in ESC RCC, these genes have not been sequenced in ESC RCC. Using capture-based and amplicon-based next-generation sequencing, we now demonstrate the consistent presence of either TSC1 or TSC2 gene mutations in pediatric ESC RCC (8/9 cases) and adult ESC RCC (6/6 cases). These included a metastatic ESC RCC which had a complete response to mTOR targeted therapy. We also found these mutations in some neoplasms with variant morphology and thus potentially expand the spectrum of ESC RCC. These include one of our adult cases which demonstrated dominant "type 2" papillary RCC morphology and 2 of 3 previously unclassified pediatric RCC with features of ESC RCC minus granular cytoplasmic stippling. We also demonstrate TSC mutations in a case of so-called "oncocytoid RCC after neuroblastoma" with identical morphology and immunoprofile, providing a molecular link between the latter and ESC RCC. In summary, ESC RCC consistently harbors actionable TSC1 or TSC2 mutations, which are infrequently seen in established subtypes of RCC. These findings support TSC1/2 mutation as a molecular marker of ESC RCC, and suggest expansion of the clinicopathologic spectrum to include neoplasms with papillary architecture, occasional cases lacking well-developed granular cytoplasmic stippling, and a subset of RCC with oncocytic features in patients who have survived neuroblastoma.
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Key Words: pediatric, renal cell carcinoma, TSC, eosinophilic solid and cystic RCC (Am J Surg Pathol 2018;42:1166-1181) E osinophilic solid and cystic (ESC) renal cell carcinoma (RCC) has recently been described as a potentially new subtype of RCC. 1,2 ESC RCC has been reported in adult female patients and has been postulated to be the sporadic counterpart to one subtype of tuberous sclerosis complex (TSC)-associated RCC. 3, 4 Histologically, these neoplasms show solid and cystic architecture, and the neoplastic cells contain voluminous eosinophilic cytoplasm with granular cytoplasmic stippling. They frequently demonstrate at least focal expression of cytokeratin 20 (CK20). All cases reported in the initial 2 series occurred in females, and none of these patients had metastases at the time that they were reported.
Our group recently reported 10 ESC RCCs within a cohort of previously "unclassified" eosinophilic RCCs in young patients, defined in that study as RCC in patients below 35 years of age. 5 Our study expanded the proposed clinicopathologic spectrum of ESC RCC in several ways. First, our ESC RCC cases occurred in young patients (median age, 27 y), including 3 teenagers. Second, 4 of our cases occurred in males. Third, one case developed metastases to the lung and liver. Fourth, 5 of our cases (50%) were multifocal. Fifth, 5 of the 8 cases tested (62.5%) demonstrated focal labeling for cathepsin K, typically a marker of MiT family translocation RCC and PEComas. We also noted, however, that some additional cases in our cohort of eosinophilic RCC closely resembled ESC RCC, but were not perfect matches. Specifically, several of these cases had many of the morphologic features (solid architecture with cysts, abundant eosinophilic cytoplasm, and focal CK20 immunoreactivity) of ESC RCC, but lacked well-developed granular cytoplasmic stippling.
Comprehensive DNA sequencing of ESC has not previously been reported. In the current study, we examined a subset of our cohort of ESC RCC in young patients for cancer-associated mutations, and found consistent inactivation of TSC genes (TSC1 or TSC2). We then screened a larger group of ESC RCC in children and adults, found similar TSC mutations, and expanded the study to analyze cases with variant morphology to potentially expand the spectrum of ESC.
MATERIAL AND METHODS

Institutional Review Board Approval
This study was approved by the Institutional Review Board of the Johns Hopkins Hospital and other participating institutions.
Cases
We screened 5 ESC RCC from young patients previously included in our prior study 5 (Prior ESC RCC #1, 2, 3, 5, 6) for cancer-associated mutations using capture-based nextgeneration sequencing (NGS). Following the identification of TSC1 or TSC2 mutations in all cases in this cohort (see the Results section), we then studied a larger series of cases (n = 34) using amplicon-based NGS to specifically assess for TSC1 and TSC2 mutations. These included 7 of the previously reported ESC RCCs from young patients (3/5 ESC RCCs initially evaluated with the hybrid capture technique [Prior ESC RCC #3, 5, and 6] along with Prior ESC RCC #4, 8, 9, and 10). 5 We also studied: 3 previously described eosinophilic RCCs from young patients which had features of ESC but were considered unclassifiable because they lacked characteristic granular cytoplasmic stippling (Unclassified ESC-like #1 to 3) 5 ; 6 new, previously unreported ESC RCCs from adults (New ESC RCC #1 to 6); 1 TSC-associated RCC; and 1 so-called "oncocytoid RCC after neuroblastoma." As negative controls, we also included 4 oncocytomas, 4 chromophobe RCCs, 4 clear cell RCCs, 3 papillary RCCs, and 1 clear cell papillary RCC, all displaying prototypical histomorphology.
DNA Extraction
Tumor hematoxylin and eosin slides were examined and marked by 2 pathologists (P.A. and D.N.P.) for subsequent macro-dissection, DNA isolation, and molecular testing. Areas enriched with tumor were then scraped from adjacent 5-µm thick formalin-fixed paraffin-embedded sections (3 to 7 unstained slides per sample) and transferred to Sarstedt (Sarstedt AG & Co. KG, Nümbrecht, Germany) screw top tubes for DNA extraction. Adjacent normal tissue was separately isolated and processed for select cases when available (Prior ESC RCC #6 and the TSC-associated RCC case).
Extraction and purification was performed with the automated Siemens Tissue Preparation System (Siemens Healthcare Diagnostics Inc., Tarrytown, NY). Genomic DNA was quantified using the Qubit 2.0 Fluorometer (Life Technologies, Carlsbad, CA).
Capture-based NGS
DNA libraries were prepared using Agilent SureSelectXT reagents (Agilent Technologies Inc., Santa Clara, CA) with genomic regions of interest captured by means of an Agilent custom-designed bait set ( > 600 genes, full coding regions; low coverage of exon 1 in a subset of genes). The libraries were sequenced to an average unique read depth of > 500× using Sequencing by Synthesis (SBS) 2×100 base pairs (bp) paired-end cluster generation on the Illumina HiSeq 2500 platform (Illumina Inc., San Diego, CA). FASTQ files were generated from Binary Cluster Files (.bcl) using the Illumina bcl2fastq version 1.8.4 software with parameters set as per vendor's specifications. FASTQ files were aligned to the human genome reference hg19 (GRCh37) using the Burrows-Wheeler Aligner version 0.7.10 algorithm with default settings. BAM files (.bam) were generated using Picard Tools version 1 
Amplicon-based NGS
DNA libraries were prepared using Illumina's TruSeq Custom Amplicon oligonucleotide probes (175 bp amplicons) designed for dual-strand sequencing (separate primer sets for positive and negative DNA strands resulting in two separately generated amplicon pools per sample), which decreases the number of false-positive calls that arise from deamination events during formalin fixation, and TruSeq Custom Amplicon Low Input Library Prep Kit as per vendor's specifications. Genomic targets included the entire coding regions for the following 19 genes: TSC1, TSC2, PTEN, MTOR, FH, VHL, NF2, BAP1, PBRM1, CDKN2A, SETD2, SMARCA4, SMARCB1, TCEB1, KMT2A, KMT2C, KMT2D, KDM5C, and KDM6A.
The libraries were sequenced using Sequencing by Synthesis 2×100 bp paired-end cluster generation on the Illumina HiSeq 2500 platform. Sequencing data was analyzed using Illumina's online BaseSpace Sequence Hub Amplicon DS version 1.2 App.
Only variants with quality scores of 100 detected in both amplicon pools were considered for further analysis. All variant calls were manually inspected in IGV for quality. Variants within homopolymeric regions were excluded from the study. CA) and genotyped using lllumina's HumanCytoSNP-850K (version 1.1) BeadChip platform (∼850,000 single nucleotide polymorphism [SNPs] ) and iScan microarray system. Data visualization was performed using KaryoStudio version 2.0 and GenomeStudio Software version 2.0 (Illumina). All determinations of chromosomal abnormalities, copy number variants, and copy-neutral loss of heterozygosity were performed manually using B-allele frequency and smoothed log-R ratio data.
TSC1/TSC2 Mutation Calling
TSC1 and TSC2 variants were considered pathogenic if they had been reported in patients with familial and/or de novo TSC in the literature or in the tuberous sclerosis Leiden Open Variation Database (LOVD; www.LOVD.nl/TSC2; http:// www.LOVD.nl/TSC1) (version 2.0 Build 36). 6 Variants that had not been previously reported were classified as either likely pathogenic (frameshift/nonsense variants considered likely impactful to gene function; pathogenic variants reported in the same genomic region) or variants of uncertain significance (VUS) (not present or present at frequencies below 0.1% in 1000 genomes database and/or located in a splice region). The following transcripts were used for annotation: TSC1-NM_000368.4; TSC2-NM_000548.3.
Immunohistochemistry
Immunohistochemistry was performed on the Benchmark XT autostainer (Ventana Medical Systems Inc., Tucson, AZ) for CK20 (ks20.8; Dako, Carpinteria, CA; prediluted).
RESULTS
ESC RCC in Young Patients From Prior Study
In our prior study, 5 we classified 10 cases as ESC RCCs. The median age was 27 years (range, 14 to 35 y). Six patients were female and 4 were male. All 10 neoplasms demonstrated the morphologic features described recently by Trpkov et al 1, 2 : solid and cystic architecture, voluminous eosinophilic cytoplasm, granular cytoplasmic stippling, and focal CK20 expression. Five of 10 ESC RCC were multifocal (1 bilateral), while 3 of 10 ESC RCC patients had histories of prior malignancy. One patient developed metastatic disease involving the lung and liver. Clinical follow-up was available for 2 of 10 patients, and they showed no evidence of disease at 4.5 and 72 months. No patient had a reported personal or family history of TSC. Moreover, we confirmed specifically in 5 cases the absence of angiomyolipoma on renal imaging, the absence of suspicious skin lesions on physical examination, and no clinical history of unexplained seizures. Of 8 cases tested, 5 (62.5%) showed focal labeling for cathepsin K by immunohistochemistry.
Capture-based NGS of a small cohort (n = 5) of the previously reported ESC RCCs from young patients (Prior ESC RCC #1, 2, 3, 5, 6) 5 demonstrated TSC mutations in all cases (4 TSC2-mutated; 1 TSC1-mutated) (Fig. 1 ). Matched normal tissue was available for one case (Prior ESC RCC #6) and was sequenced, confirming the somatic status of the variants identified. Of note, this patient had multifocal tumors (paraffin tissue from the other tumor in the same kidney was not available for testing). Four of the 7 alterations detected (TSC2 p.Y130X; TSC2 splice acceptor variant c.976-1G > A between exon 10 and 11; TSC2 p.L361Sfs; TSC1 p.Y761X) have been previously reported in patients with TSC and are thought to be pathogenic, [7] [8] [9] [10] [11] [12] while the other 3 (TSC2 p.L243Hfs; TSC2 p.D1677Afs; TSC1 p.L853Cfs) are considered to be likely pathogenic. 6, 7 TSC mutations were detected by amplicon-based NGS in 6 of 7 ESC RCCs from our previous study, 5 bringing the total to 8 of 9 ESC RCC in young patients associated with TSC mutations. In 4 of 8 cases, mutations were biallelic. Molecular results were orthogonally confirmed in the 3 cases (Prior ESC #3, 5, 6) tested by both methods with the exception of the TSC2 p.Y130X mutation detected by capture-based NGS in Prior ESC RCC #6. However, coverage of this region (chr16:2104297-2104441) by amplicon-based NGS was present in only one of 2 amplicon pools for that specimen. Among the prior ESC RCC cases tested using amplicon-based NGS only, 2 of the alterations (TSC2 p.F73Lfs; TSC2 c.774+1G > A), both detected in Prior ESC RCC #9, have been previously reported in cases of TSC 6, 8, 13 and are thought to be pathogenic, 2 (TSC2 p.L853Afs; TSC1 p.P641Cfs) are considered likely pathogenic, and 1 (TSC2 c.1717-1G > C) a VUS.
Of note, prior ESC RCC #5, which recurred as liver metastases, harbored a TSC2 mutation. Following clinical progression on two tyrosine kinase inhibitors, this patient had a complete clinical response to the mTOR inhibitor everolimus, and remains disease-free 8 years later.
We re-reviewed the single case of ESC RCC in a young patient (14-y-old female) in which we did not detect TSC mutations (Prior ESC RCC #10). On review, this neoplasm demonstrated typical morphologic features of ESC RCC throughout (Fig. 2) . Review of the sequencing data showed adequate overall coverage for TSC1 and TSC2 (average depth of coverage, > 1000 reads per amplicon pool), but scattered low covered areas (< 100 reads) in either one or both amplicon pools.
SNP array analysis showed whole chromosome gains of chromosomes 5, 11, and 14 in Prior ESC RCC #5 and segmental losses of chromosome 6 (6p22.1-p21.32; 6q21-q22.31; 6q25.2-q27) in Prior ESC RCC #2. No chromosomal aberrations were identified in Prior ESC RCC#6. SNP array was attempted in Prior ESC RCC #1 and #3 but could not be completed.
None of the 7 Prior ESC RCC studied demonstrated known or likely pathogenic mutations in any of the 17 other RCC-associated genes (PTEN, MTOR, FH, VHL, NF2, BAP1, PBRM1, CDKN2A, SETD2, SMARCA4, SMARCB1, TCEB1, KMT2A, KMT2C, KMT2D, KDM5C, and KDM6A) in the amplicon-based NGS panel (not shown). A variant of unknown significance, however, was seen in Prior ESC RCC #9 in the VHL gene, p.N193K (NM_000551.3, VAF 40%).
The clinicopathologic features of these cases along with mutations are summarized in Table 1 .
Previously Unreported Adult ESC RCC
We identified 6 new previously unreported adult cases of ESC RCC from our files. These patients ranged in age from 42 to 66 years, and all were females. The clinicopathologic features of these cases are summarized in Table 1 . None of these cases had a reported clinical history or stigmata of TSC. Moreover, we confirmed in 5 cases specifically that no angiomyolipomas were present on renal imaging, no lesions were found on skin examination, and there was no history of seizures. Five of the 6 cases had been submitted in consultation to rule out MiT family translocation RCC. All 5 these cases demonstrated typical ESC RCC features, including solid and cystic architecture and voluminous eosinophilic cytoplasm with granular cytoplasmic stippling. All 4 cases tested demonstrated characteristic focal CK20 immunoreactivity (Fig. 3) . All 5 cases demonstrated focal immunoreactivity for cathepsin K, but were negative for TFE3 and TFEB rearrangement by fluorescence in situ hybridization. The sixth case of adult ESC RCC identified in the routine files of The Johns Hopkins Hospital was originally classified as a papillary RCC (Fig. 4) . On review by one author (P.A.), this neoplasm had predominantly papillary architecture but displayed characteristic granular cytoplasmic stippling of ESC RCC and focal immunoreactivity for CK20.
All 6 of these neoplasms demonstrated TSC mutations (4 TSC1-mutated; 2 TSC2-mutated). In two cases, mutations were biallelic. Only one of the 8 variants detected (TSC2 p.G1577Afs) in the new adult ESC cohort is thought to be pathogenic, having been previously reported in a familial case of TSC. 14 Six variants are considered to be likely pathogenic with analogous variants previously reported in familial and sporadic cases of TSC (TSC1 p. L612X 15, 16 ; TSC2 p.V1139Lfs 6 ; TSC2 p.I64Dfs 6 ; TSC1 p. K148Nfs 6, 13 ; TSC1 p.H660Rfs 6 ; and TSC1 p.S838Rfs 6 ), while 1 variant (TSC1 p.D426Y, New ESC RCC#4), is considered a VUS that appears to occur at a low frequency (rs765695557, ExAC 0.003%) in population databases and has not been reported in the literature or LOVD in individuals with TSC-related sequelae. 
TSC-associated RCC Case
This patient was a 9-year-old boy with a clinical history of TSC who was found to have a 9 mm renal mass. The neoplasm demonstrated nested papillary architecture and variably clear cytoplasm with ESC-like granular cytoplasmic stippling. The neoplasm demonstrated patchy immunoreactivity for cathepsin K and focal labeling for CK20, similar to that previously reported in ESC RCC (Fig. 5) .
Molecular analyses of this case demonstrated both germline and somatic alterations in the TSC2 gene. Multiple TSC2 polymorphisms were detected in both the normal and tumor tissue (TSC2 c.482-3C > T, TSC2 p. L826M, TSC2 p.S1774T, and TSC2 p.G1439D) as well as one pathogenic variant (TSC2 p.M276Vfs) that has been reported in one familial case of TSC 8 and multiple de novo cases. 17, 18 A splice donor variant (TSC2 c.1119+1G > C) of unknown significance was also present in the tumor tissue. While this variant has one pathogenic submission in ClinVar (no assertion criteria provided, accessed February 18, 2018) and similar variants in the region reported in the LOVD database as pathogenic (TSC2 c.1119+1G > A; TSC2 c.1119+2T > G), 6 the clinical significance of this specific splice variant is not certain. 
Unclassified RCC With Features of ESC
We noted in our prior study 5 that 4 of 11 unclassified RCCs showed some features of ESC RCC, including focal CK20 expression, but lacked well-developed granular cytoplasmic stippling. We obtained material from 3 of these 4 cases, and found TSC mutations in 2 of 3 (Figs. 6, 7) . Both of the TSC-mutated cases demonstrated prominent cell borders, giving a plant-like appearance to the tumor cells, along with at least focally prominent nucleoli. One had prominent cytoplasmic vacuolization (Fig. 6) . One demonstrated focal immunoreactivity for Melan A. On re-review, no evidence of granular cytoplasmic stippling was found. Three TSC alterations were identified, 1 pathogenic (TSC2 p.R1459X, reported in over 40 cases of familial 16, 19 and sporadic cases 6,8,13,17 TSC) and 2 likely pathogenic (TSC2 p.Y1650Tfs, TSC1 p.N77Lfs) with similar variants reported in a case of type 1 segmental postzygotic mosaicism of TSC 20 and familial TSC, 21 respectively. None of these patients had a reported clinical history of TSC. Moreover, in unclassified ESC-like RCC case 3, we were able to specifically confirm the absence of renal angiomyolipomas on imaging, normal skin examination, and no clinical history of seizures.
None of the 3 unclassified ESC-like RCC studied demonstrated known or likely pathogenic mutations in any of the 17 other RCC-associated genes (PTEN, MTOR, FH, VHL, NF2, BAP1, PBRM1, CDKN2A, SETD2, SMAR-CA4, SMARCB1, TCEB1, KMT2A, KMT2C, KMT2D, KDM5C, and KDM6A) in the amplicon-based NGS panel (not shown).
So Called "Oncocytoid RCC After Neuroblastoma"
This patient was a 40-year-old female who had undergone adrenalectomy for neuroblastoma at the age of 6 months followed by adjuvant radiation therapy. Her course was complicated by chronic renal insufficiency associated with ureteral obstruction. At the age 40, she was found to have a renal mass on imaging, which proved to be a 3 cm, largely solid oncocytic neoplasm. The neoplasm had focal areas of papillary architecture, clusters of foamy macrophages, and lesional cells with abundant, voluminous eosinophilic cytoplasm associated with granular cytoplasmic stippling similar to that seen in ESC RCC. The neoplasm demonstrated focal immunoreactivity for CK20 (rare positive cells), also similar to the pattern of ESC RCC. Fluorescence in situ hybridization showed no evidence of TFE3 or TFEB gene rearrangement, arguing against MiT family translocation carcinoma. SDHB immunoreactivity was intact. These features are typical of a subset of those reported by Medeiros et al 22 as "oncocytoid renal cell carcinoma after neuroblastoma", though our patient was an adult (Fig. 8) .
This neoplasm demonstrated 2 TSC2 mutations: TSC2 p.Q397X and TSC2 p.C244F. A similar variant to the TSC2 p.Q397X found in this case has been reported in a patient with TSC. 9 Although the other variant detected, TSC2 p.C244F, has not been previously reported, missense variants involving this amino acid have been reported as "probably pathogenic" in the LOVD database (last accessed February 18, 2018) . 6 This neoplasm did not demonstrate known or likely pathogenic mutations in any of the 17 other RCC-associated genes (PTEN, MTOR, FH, VHL, NF2, BAP1, PBRM1, CDKN2A, SETD2, SMARCA4, SMARCB1, TCEB1, KMT2A, KMT2C, KMT2D, KDM5C, and KDM6A) in the amplicon-based NGS panel (not shown). A variant of unknown significance, however, was seen in the NF2 gene, p.E463K (NM_000268.3, VAF 63%).
Negative Control Cases
None of the 16 negative control cases (4 oncocytomas, 4 chromophobe RCCs, 4 clear cell RCCs, 3 papillary RCCs, and 1 clear cell papillary RCC) demonstrated TSC1 or TSC2 mutations. Figure 9 summarizes the mutations found in TSC1 and TSC2 in this study.
DISCUSSION
In this study, we demonstrate the consistent presence of TSC mutations in ESC RCC. Given the novel nature of these findings, we used 2 orthogonal sequencing techniques to assess for these mutations and showed concurrent results in cases studied by both methods. Six of 16 cases harbored two mutations in either TSC1 or TSC2. Additional mechanisms of allelic inactivation (eg, loss of heterozygosity, DNA methylation, etc.) are suspected in the other 10 cases. We did not find TSC mutations in our relatively small cohort of control cases studied, which is compatible with the relatively low frequency (∼5%) of TSC mutations found in the more common types of RCC reported in larger cohorts in the literature (Tables 2, 3 ). Our results are not entirely unexpected. ESC has been postulated to be analogous to a subtype of RCC consistently identified in TSC patients, 33 termed "eosinophilic macrocystic" RCC in one study. 3 Moreover, Trpkov and colleagues recently demonstrated loss of heterozygosity at the TSC1 locus and copy number gains at TSC2 in ESC RCC, though these genes were not sequenced. The presence of somatic TSC mutations in our cases supports the concept that ESC RCC is the sporadic counterpart of TSC-associated RCC.
One consideration is that the TSC1/2 mutations we detected are germline, and that some/all of these patients have TSC, which is a genetic disorder with known variable penetrance. 34 The minimal number of cases in the study with available non-neoplastic tissue from the kidney (one TSCassociated RCC, Prior ESC #6) is certainly a weakness of the study, though it reflects the consultative nature of these cases such that normal tissue was impossible for us to obtain. However, we strongly believe that the mutations we detected here are somatic for several reasons. First, no patient has clinical evidence of TSC, including 11 cases in which we directly confirm that renal angiomyolipomas, suspicious skin lesions, and history of unexplained seizures were not present. This is significant because 90% of patients with TSC have skin lesions (seen at all ages), 50% to 75% will have angiomyolipomas on renal imaging, and > 70% to 80% will demonstrate a history of epilepsy. 34 Second, although detailed clinical history was not available for Prior ESC#6, normal tissue DNA was available and did not show evidence of TSC alterations.
Our results support all of the novel associations of ESC RCC reported previously by our group, 5 in that those cases consistently demonstrated the same TSC mutations seen in more typical adult ESC RCC. First, we document that TSC-mutated ESC can occur in young patients, as 2 of our TSC-mutated cases occurred in teenagers. Taken together with our prior study, 5 these findings indicate that the majority of previously unclassifiable pediatric RCC with eosinophilic cytoplasm can now be associated with one of 3 specific molecular alterations: fumarate hydratase deficiency, succinate dehydrogenase (SDH) deficiency, or TSC mutations. The former two can be readily identified by fumarate hydratase and SDHB immunohistochemistry, even though, as shown previously, 5 the morphology is often not that typically reported for these neoplasms in adults. Second, we confirm TSC-mutated ESC RCC in two males. Third, we confirm that TSC-mutated ESC RCC (Prior ESC RCC #5) may metastasize. Supporting this idea, an additional morphologically defined ESC RCC with lymph node metastasis has recently been reported. 35 The complete response of the metastases of prior ESC RCC #5 with the rapamycin analog everolimus highlights the significance of the TSC mutations and is consistent with previously reported responses in patients with other TSCassociated neoplasms including subependymal giant cell astrocytoma and renal angiomyolipoma. Fourth, we confirm that TSC-mutated ESC RCC can be multifocal in 4 of our previously reported cases, one of which was confirmed to harbor somatic mutations. Finally, we confirm that TSC-mutated ESC RCC typically demonstrates focal immunoreactivity for cathepsin K, which we found in all 5 new TSC-mutated adult ESC cases tested and over half of the previously reported ESC RCC in young patients. 36 , 37 The presence of TSC mutations in ESC provides a plausible mechanism for focal cathepsin K immunoreactivity.
In normal cells, the TSC gene products, TSC1 (hamartin) and TSC2 (tuberin), form a GTPase activating protein complex and inhibit mTOR complex 1 (mTORC1). Loss or inhibition of the TSC complex leads to constitutive activation of mTORC1 and dysregulation of multiple cellular pathways including cell growth and proliferation. In osteoclasts, inhibition of mTORC signaling inhibits cathepsin K expression, so in ESC RCC one could hypothesize that increased mTORC signaling secondary to TSC mutations increases cathepsin K expression. 38, 39 Interestingly, cathepsin K, a lysosomal cysteine protease normally regulated by MITF in activated macrophages and osteoclasts, is typically overexpressed in perivascular epithelioid cell tumors (PEComas) 40 and pulmonary lymphangioleiomyomatosis, 41 which also demonstrate TSC1/2 inactivation and mTOR hyperactivation, as well as MiT family translocation RCCs. 36, 37 Along these lines, we noted diffuse cathepsin Metastatic lesions from primary-metastatic paired samples were excluded from the mutation counts if they contained identical mutations to the primary lesion.
K expression and focal CK20 labeling in one case of TSCassociated RCC studied in our cohort, though we have not seen consistent cathepsin K immunoreactivity in all TSCassociated RCC (P. Argani, unpublished observations). Our findings also potentially expand the morphologic spectrum of ESC RCC. Particularly noteworthy was New ESC RCC #4, which had extensively papillary architecture and was originally classified as papillary RCC. On careful review, this neoplasm demonstrated the characteristic granular cytoplasmic stippling of ESC RCC along with focal CK20 immunoreactivity, as well as one small solid tubular area that was more typical of ESC RCC. It should be noted that focal papillary areas in ESC RCC were noted in a minority of cases in the studies by Trpkov et al. 1, 2 These findings suggest that a subset of so called "type 2 papillary RCC," now considered by the 2016 WHO classification to be a pattern that can be adopted by a wide range of RCC rather than a specific entity, may be related to ESC RCC. 42 Also, potentially expanding the spectrum of ESC RCC were 2 previously unclassified ESC-like cases notable for their prominent cell borders, reminiscent of the cytology of chromophobe RCC, and absence of well-defined, granular cytoplasmic stippling that now demonstrate TSC mutations. Of note, focal cytology reminiscent of chromophobe RCC was also noted in 2 cases reported by Trpkov et al 2 ; in our cases, the chromophobe RCC-like appearance was the dominant histologic finding. Also, one of these cases demonstrated focal immunoreactivity for Melan A, which has not been previously reported in ESC RCC, and both focally displayed more prominent nucleoli than those typically seen ESC RCC. One demonstrated prominent cytoplasmic vacuolization. Given that TSC mutations can rarely be detected in a small percentage of non-ESC RCC (see below), we believe that TSC mutation detection alone does not make the diagnosis of ESC. However, the shared morphologic features and TSC mutations, given the high frequency of TSC mutations in ESC ( > 90%) relative to other subtypes of RCC (< 5%), strongly favor that these lesions are related to ESC.
While the detection of TSC mutations in ESC RCC suggests that molecular diagnostics can help clarify the spectrum of these lesions, several caveats should be noted. First, as noted above TSC mutations have been reported in small subset of other RCC types (Tables 2, 3) . [23] [24] [25] [28] [29] [30] [31] [32] We reviewed online images of RCC associated with TSC mutations from the TCGA Kidney Renal Clear Cell Carcinoma cohort 31 present on the cBioPortal for Cancer Genomics website (www.cbioportal.org) 26, 27 and found that at least some of the cases reported as clear cell RCC are morphologically compatible with that diagnosis (Supplemental Fig. 1 , Supplemental Digital Content 1, http://links. lww.com/PAS/A646). Second, it also remains possible that cases morphologically consistent with ESC RCC but lacking TSC mutations may harbor other alterations in the mTOR pathway that effects a similar phenotype. This concept is exemplified by translocation associated sarcomas, where variant fusions commonly exist such that the absence of a specific gene fusion does not exclude the diagnosis of most translocation-associated sarcomas. Along these lines, we rereviewed the morphology of the one pediatric ESC RCC from our prior study which lacked detectable TSC mutations, and found it to be typical of ESC RCC. We suspect that this lesion may harbor a genetic alteration in a TSC gene that is not detectable using our techniques or a mutation that effects a similar phenotype to ESC RCC, perhaps targeting one of the other mTOR pathway genes.
The presence of TSC mutations in ESC RCC is intriguing given that a higher frequency (∼20%) of unclassified high grade RCC in one recently published cohort The query was performed using cBioPortal for Cancer Genomics (www.cbioportal.org) 26, 27 accessed on February 15, 2018. *Two cases from the renal non-clear cell RCC cohort 23 were annotated as classic chromophobes: one case with a TSC1 missense mutation; and the other case with one TSC2 frameshift mutation and one TSC2 nonsense mutation. Three cases were annotated as "papillary": 2 cases with one TSC1 missense mutation each; and the third case with one TSC2 missense mutation. This combined query contains samples from 7 studies: (1) Kidney Renal Clear Cell Carcinoma (BGI, Nat Genet 2011) 24 ; (2) 28 ; and (7) Multiregion Sequencing of Clear Cell Renal Cell Carcinoma (IRC, Nat Genet 2014). 32 harbor mTOR pathway mutations, including 11% with TSC mutations. 28 Given that we have established the malignant potential of ESC RCC in the current study, one could speculate that some of the latter cases represent higher grade lesions in the ESC RCC spectrum. Regardless, the findings further support the need to consider therapy targeting the mTOR pathway in these RCC.
Our findings also support the link between the entities previously described as "oncocytoid renal cell carcinoma status post neuroblastoma" and ESC RCC. The former was proposed as a distinct neoplasm in the 2004 WHO classification of renal neoplasia, but was downgraded to a provisional entity in the current 2016 classification. It has been noted that such RCC occurring after neuroblastoma represent a heterogenous group with many representing post therapy MiT family translocation carcinomas. 33, 43 However, some of these cases have had a striking "oncocytoid" appearance described in the original paper by Medeiros et al, 22 which has been noted to overlap with ESC RCC and TSC-associated RCC. 33 Our identification of a TSC mutation in one such case, along with the shared focal CK20 immunoreactivity, further supports this association.
In summary, we have demonstrated the consistent presence of actionable TSC mutations in an expanded spectrum of ESC RCCs. Our findings not only support the pathogenesis of ESC RCC as a sporadic counterpart of a subset of TSC-associated RCC with metastatic capacity, but also broaden the clinical presentation of ESC RCC to include males and multifocal lesions. Furthermore, we show that ESC RCC overlaps with a subset of RCCs that occur in patients who have survived neuroblastoma, socalled "oncocytoid RCC after neuroblastoma."
